Extracorporeal blood purification therapy for sepsis and systemic inflammation: its biological rationale.
EBPTs represent a promising new approach to the adjuvant treatment of severe sepsis, septic shock and MODS. Their technology is rapidly evolving and pilot animal and human studies are now taking place to prepare the territory for the first large randomized controlled trial. The rationale for EBPT is reasonable and the initial data are encouraging. The correct technology and molecular targeting, however, are still being explored. Once the best technology has been determined, it is likely that phase II and phase III trials will be performed to test the hypothesis that these therapies can indeed alter mortality in severe inflammatory multiorgan dysfunction.
Bellomo
R
R
Department of Intensive Care, Austin and Repatriation Medical Centre, Heidelberg, Melbourne, Vic., Australia. rb@austin.unimelb.edu.au
Baldwin
I
I
Ronco
C
C
D016638:Critical Illness; D006440:Hemofiltration; D006801:Humans; D009102:Multiple Organ Failure / Q000628:therapy*; D018805:Sepsis / Q000628:therapy*